Audio Library

Vascular Adviser News

Preserving Limbs And Avoiding Repeat Revascularization In Patients With PAD

In this episode, Dr Sonia Anand and Professor Rupert Bauersachs discuss practical perspectives on how vascular surgeons can improve outcomes in patients with symptomatic PAD undergoing peripheral revascularization.

PP-XAR-ALL-2447-1

PP-XAR-ALL-2448-1

The results of the COMPASS trial can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa1709118
A subgroup analysis of patients with PAD in the COMPASS trial can be accessed here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32409-1/fulltext
A subanalysis of the COMPASS trial investigating the net clinical benefit of dual pathway inhibition is available here: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046048
The findings from the VOYAGER PAD trial can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa2000052
The study investigating the total ischaemic event reduction with rivaroxaban in VOYAGER PAD can be accessed here: https://www.sciencedirect.com/science/article/pii/S0735109721050166
A meta-analysis of the COMPASS and VOYAGER trials is available here: https://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwab128/6360030
More information on the effect of concomitant clopidogrel on the efficacy and safety of rivaroxaban and aspirin in VOYAGER can be found here: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.050465
The CASPAR paper can be accessed here: https://www.jvascsurg.org/article/S0741-5214(10)00981-X/fulltext
The Dutch BOA trial paper is available here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)07199-8/fulltext
The summary of product characteristics for rivaroxaban can be found here: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf
The summary of product characteristics for clopidogrel can be found here: https://www.medicines.org.uk/emc/product/5288/smpc

Keith Fox About The Updated CCS ESC Guidelines 2019

Despite current optimised medical treatment, patients with CAD or PAD remain at high risk of cardiovascular events. With the European approval of rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin, and new European guidelines’ recommendations on vascular protection, we are in exciting times. Join James Rudd in this episode of the Thrombosis Adviser Podcast series discussing together with Keith Fox - Professor of Cardiology at the University of Edinburgh - how to interpret the ESC 2019 Guidelines on Chronic Coronary Syndrome.

PP-XAR-ALL-1571-1

Dr. Alexander Cohen highlighting the updated ESC recommendations

Recent real-world evidence, as well as results from Phase 3 trials, have shed light on the efficacy and safety of NOACs for the treatment of VTE in different patient populations. My name is James Rudd and in this episode of the Thrombosis Adviser podcast series I am delighted to welcome Ander Cohen – Vascular Physician and Epidemiologist at Guy’s and St Thomas’ NHS Foundation Trust in London – to discuss practical considerations for the use of NOACs in the treatment of patients with VTE.

PP-XAR-ALL-1570-1